We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gas Bubbles Used to Fight Tumors

By Biotechdaily staff writers
Posted on 03 Aug 2006
Researchers are experimenting with gas bubbles used like corks to block oxygen flow to tumors or to deliver drugs.

The process of blocking blood flow to a tumor is called embolization, and using gas bubbles is a new technique in embolotherapy. More...
What makes this method so promising is that the technique allows clinicians to control precisely where the bubbles are formed, so blockage of blood flow to surrounding tissue is minimal, according to Dr. Joseph Bull, assistant professor of biomedical engineering at the University of Michigan (U-M; Ann Arbor, USA).

The study of Dr. Bull and collaborator Dr. Brian Fowlkes, an associate professor in the department of radiology in the U-M Medical School, is currently focused on the vaporization and transport fundamentals that must first be determined to translate this developmental technique to the clinic.

In conventional embolotherapy techniques, the so-called cork that clinicians use to stop the blood flow--called an emboli--is solid. For instance, it could be a blood clot or a gel. A key problem with these approaches is restricting the emboli to the tumor to minimize destruction of surrounding tissue, without using very invasive procedures, according to Dr. Bull. The emboli must be delivered by a catheter placed into the body at the tumor site. Gas bubbles, however, allow very precise delivery because their formation can be controlled and directed from the outside, by focused high intensity ultrasound.

This planned technique is actually a two-step process, according to Dr. Bull. First, a flow of encapsulated superheated perfluorocarbon liquid droplets is delivered into the body by way of an intravenous injection. The droplets are small enough that they do not lodge in vessels. Clinicians image the droplets with conventional ultrasound, and once the droplets reach their destination, scientists blast them with high intensity ultrasound. The ultrasound acts like a pin popping a water balloon. After the shell pops, the perfluorocarbon expands into a gas bubble that is about 125 times larger in volume than the droplet.

"If a bubble remained spherical its diameter would be much larger than that of the vessel,” Dr. Bull said. "So it deforms into a long sausage-shaped bubble that lodges in the vessel like a cork. Two or three doses of bubbles will occlude most of the [blood] flow.” Without blood flow, the tumor dies. Because the bubble is so big, it is important to get the correct vessel in order not to damage it.

"How flexible the vessel is plays a very important role in where you do this,” Dr. Bull said. The embolotherapy study will be published in the August 2006 issue of the Journal of Biomechanical Engineering.

The technique could be very valuable in treating specific cancers, such as renal cancer and hepatocellular carcinoma, the most common form of liver cancer, which has a high mortality rate. However, cirrhosis of the liver makes it difficult to treat by the conventional method of excising the tumor and surrounding tissue, because so much of the liver is already damaged.



Related Links:
University of Michigan

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.